Contraception
Volume 77, Issue 5 , Pages 371-376, May 2008

Hormonal contraception and HIV prevalence in four African countries

  • Pauline M. Leclerc

      Affiliations

    • Institut Pasteur, Epidémiologie des Maladies Emergentes, and Université Paris VI, 75015 Paris, France
    • Corresponding Author InformationCorresponding author. Institut Pasteur, Epidémiologie des Maladies Emergentes, 25 rue du Docteur Roux, 75015 Paris, France. Tel.: +33 1 40 61 39 65; fax: +33 1 45 68 88 76.
  • ,
  • Nicolas Dubois-Colas

      Affiliations

    • Institut Pasteur, Epidémiologie des Maladies Emergentes, and Ecole Normale Supérieure, 94230 Cachan, France
  • ,
  • Michel Garenne

      Affiliations

    • Institut Pasteur, Epidémiologie des Maladies Emergentes, and Institut de Recherche pour le Développement, Paris, France

Received 6 October 2007; received in revised form 14 January 2008; accepted 14 January 2008. published online 20 March 2008.

Abstract 

Background

The HIV seroprevalence among women aged 15–24 years was compared according to their pattern of contraceptive use in four African countries: Kenya, Lesotho, Malawi and Zimbabwe.

Study Design

Data were derived from Demographic and Health Surveys (DHS) conducted between 2003 and 2006 on representative samples, totaling 4549 women.

Results

It is indicated that users of depo-medroxyprogesterone acetate (DMPA) have a significantly higher seroprevalence than nonusers [odds ratio (OR)=1.82, 95% CI=1.63–2.03] and higher than users of oral contraceptives and users of traditional methods. The results were confirmed in a multivariate analysis including as controls, age, duration since first intercourse, urban residence, education, number of sexual partners in the last 12 months and marital status. A somewhat smaller net effect (OR=1.34, 95% CI=1.10–1.63) was found. In contrast, oral contraceptives and traditional methods did not show any risk for HIV (OR=0.96 and 0.92, respectively).

Conclusion

The increased risk of DMPA was present in three of the four countries investigated, and significant in Zimbabwe and Lesotho, the countries with the highest HIV seroprevalence. The HIV risk attributable to DMPA remained small altogether and was estimated as 6% in the four countries combined.

Keywords: HIV/AIDS, HIV seroprevalence, Hormonal contraception, Pill, Depo-Provera, DHS, Sub-Saharan Africa

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0010-7824(08)00061-9

doi:10.1016/j.contraception.2008.01.012

Contraception
Volume 77, Issue 5 , Pages 371-376, May 2008